Stock Analysis of Midatech Pharma PLC ADR (MTP) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code MTP
Close 0.270
Change 0.0166 / 6.55 %
Volume 1866.69 K
Vol Change -3960.08 K / 67.96 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Low Growth Stock
Value Index No Significant Value
Profitability Index No Significant Profitability
Stability Index Very Low Stability Stock


Fundamental View of Midatech Pharma PLC ADR
PE (TTM)

0.847

Excellent
Price / Book

1.16

Very Good
Price / Sales

12.00

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

1872.14 K

Enterprise Value

-8023.86 K

ROA (TTM)

100.51

Excellent
ROE (TTM)

137.12

Excellent
Net Margin (TTM)

1416.26

Excellent
Revenue

20.93 %

699000
Net Profit

40.22 %

-7656.00 K
Debt to Equity

0.051

Excellent
Altman Z Score

-20.94

Very Poor
Quick Ratio

0

Poor
Cash Ratio

5.29

Very Good


Highs/Lows of Midatech Pharma PLC ADR
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.2869 5.89 % 1.54 % 0.2980.240211-Apr-2312-Apr-23
Two Week0.4217 35.97 % 3.42 % 0.420.240231-Mar-2312-Apr-23
One Month1.496 81.95 % 5.60 % 1.63960.240214-Mar-2312-Apr-23
Three Month2.6 89.62 % 5.95 % 3.360.240206-Feb-2312-Apr-23
Six Months7.48 96.39 % 17.48 % 8.680.240219-Oct-2212-Apr-23
One year18.8 98.56 % 27.52 % 65.00.240223-Sep-2212-Apr-23
Two year40.6 99.33 % 29.70 % 65.00.240223-Sep-2212-Apr-23
Five year800.0 99.97 % 85.46 % 65.00.240223-Sep-2212-Apr-23


Technical View of Midatech Pharma PLC ADR
RSI

20.22

Mild Bullish
MACD

-0.421

Strong Bullish
ADX

50.25

Strong Bearish
Super Trend

0.691

Mild Bearish
Williams %R

-97.86

Mild Bullish
CCI

-66.71

Bullish


EMA 5

0.282

Mild Bearish
EMA 15

0.525

Mild Bearish
EMA 50

1.57

Strong Bearish
EMA 100

3.26

Strong Bearish
SMA 100

2.93

Strong Bearish
SMA 200

7.34

Strong Bearish
SMA 5 / 20

0.270 / 0.699

Mild Bearish
SMA 15 / 50

0.469 / 1.63

Strong Bearish
SMA 50 / 200

1.63 / 7.34

Strong Bearish




Charts of Midatech Pharma PLC ADR


Returns of Midatech Pharma PLC ADR with Peers
Period / StockMTPATHXBLCMDRMA
1 Week-5.89%32.50%-12.83%1070.89%
1 Mth-81.95%-90.29%-48.44%1324.21%
3 Mth-89.62%-95.44%-47.08%813.04%
6mth-96.39%-96.21%-51.89%500.00%
1 Year-98.56%-98.55%-78.70%56.13%
2 Year-99.33%-99.89%-91.10%-61.96%
5 Years-99.97%-99.93%-99.61%-99.47%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Midatech Pharma PLC ADR with Peers
Ratio / StockMTPATHXBLCMDRMA
PE0.847-0.0149-369.13-1.99
P/B1.16-0.0236567.072.65
ROA100.51-193.28-47.83-112.87
ROE137.1200-132.91
Debt To Equity0.051000
Revenue699000
20.93 % 		80000.00
98.50 % 		1508.00 K
100433 % 		0
%
Net Income-7656.00 K
40.22 % 		-37507.00 K
44.89 % 		-22378.00 K
89508.78 % 		-7330.32 K
23.73 %


Technicals of Midatech Pharma PLC ADR with Peers
Technical / StockMTPATHXBLCMDRMA-
ADX50.2536.4212.8428.48
CMF-0.294-0.5060.365-0.0129
MFI12.2770.7816.3866.07
RSI20.2225.4134.9780.63
MACD Abv SignalTrueFalseFalseTrue
Price Above 50 MAFalseFalseFalseTrue-
Price Above 200 MAFalseFalseFalseTrue-


About : Midatech Pharma PLC ADR

Address : 1 Caspian Point, Cardiff, United Kingdom, CF10 4DQ
Tel : 44 29 2048 0180
URL : https://www.midatechpharma.com
Code : MTP, ISIN : US59564R3021, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 07_Dec_2015
Employee Count : 20

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.


Note : All Data Generated at the End of Trading Hours (EOD Data)